Synergy of Platform
Our Epitope Steering technology along with a StableHu™ Antibody Optimizer, EngageTx™, and ShieldTx™, form a suite of solutions covering every aspect of pre-clinical drug development, from precision targeting to safety, embodying our commitment to innovation and excellence.
Our AI-powered platform aims to precisely discover on-target, on-epitope antibodies, shortening the path from concept to clinic.
Speed and Efficiency
With our advanced technologies, we reduce trial and error, accelerating the pre-clinical drug development process and saving valuable time and resources.
We are committed to building and sustaining long term partnerships with shared success. Our current collaborations include Eli Lilly, the National Institute of Allergy and Infectious Diseases (an institute of the NIH), and more.